Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Go back to Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 0.71 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.71 | 52 Week High | $9.58 | |||
| Open | $0.71 | 52 Week Low | $2.34 | |||
| Day High | $0.71 | P/E | N/A | |||
| Day Low | $0.71 | EPS | $-0.34 | |||
| Volume | 2,471 | |||||
